Gerson Peltz

3.5k total citations · 1 hit paper
34 papers, 1.8k citations indexed

About

Gerson Peltz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gerson Peltz has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Gerson Peltz's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Gerson Peltz is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Gerson Peltz collaborates with scholars based in United States, Australia and Italy. Gerson Peltz's co-authors include Holger Thurm, Todd M. Bauer, Alice T. Shaw, Benjamin Solomon, Enriqueta Felip, Tony Mok, Anna Polli, Anna Maria Calella, Geoffrey Liu and Maureen Sanderson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gerson Peltz

33 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gerson Peltz

Since Specialization

Citations

This map shows the geographic impact of Gerson Peltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerson Peltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerson Peltz more than expected).

Fields of papers citing papers by Gerson Peltz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerson Peltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerson Peltz. The network helps show where Gerson Peltz may publish in the future.

Co-authorship network of co-authors of Gerson Peltz

This figure shows the co-authorship network connecting the top 25 collaborators of Gerson Peltz. A scholar is included among the top collaborators of Gerson Peltz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerson Peltz. Gerson Peltz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN 2023 ·JTO Clinical and Research Reports ·Hidetoshi Hayashi, Shunsuke Teraoka, Yasushi Goto, Toru Kumagai, Makoto Nishio, Shunichi Sugawara, Satoshi Oizumi, (unknown), (unknown), Gerson Peltz, Terufumi Kato	3
2	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs 2021 ·Annals of Oncology ·Enriqueta Felip, Alice T. Shaw, Alessandra Bearz, D. Ross Camidge, Benjamin Solomon, Jessica R. Bauman, Todd M. Bauer, Solange Peters, Francesca Toffalorio, Antonello Abbattista, Holger Thurm, Gerson Peltz, Robin Wiltshire, Benjamin Besse	68
3	1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·Benjamin Solomon, Tony Mok, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi‐Long Wu, Óscar Arrieta, Anna Maria Calella, Gerson Peltz, Anna Polli, Holger Thurm, Todd M. Bauer	2
4	Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer 2021 ·Clinical Pharmacology & Therapeutics ·Joseph Chen, Ana Ruiz-Garcı́a, Leonard P. James, Gerson Peltz, Holger Thurm, Jill S. Clancy, (unknown)	16
5	First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer breakdown → 2020 ·New England Journal of Medicine ·Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazières, Dong‐Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Benjamin Solomon	649
6	LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study 2020 ·Annals of Oncology ·Benjamin Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, (unknown), Julien Mazières, Dongwook Kim, Tony Mok, Anna Polli, (unknown), Anna Maria Calella, Gerson Peltz, Alice T. Shaw	12
7	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer 2020 ·Lung Cancer ·Solange Peters, Alice T. Shaw, Benjamin Besse, Enriqueta Felip, Benjamin Solomon, Ross A. Soo, Alessandra Bearz, Shirish M. Gadgeel, Chia‐Chi Lin, Steven Kao, Takashi Seto, Elizabeth T. Masters, Antonello Abbattista, Jill S. Clancy, Holger Thurm, Arlene Reisman, Gerson Peltz, D. Ross Camidge	15
8	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer 2020 ·Targeted Oncology ·Todd M. Bauer, Alice T. Shaw, Melissa L. Johnson, Alejandro Navarro, Justin F. Gainor, Holger Thurm, Yazdi K. Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip	79
9	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial 2019 ·The Lancet Oncology ·Alice T. Shaw, Benjamin Solomon, Rita Chiari, Gregory J. Riely, Benjamin Besse, Ross A. Soo, Steven Kao, Chia‐Chi Lin, Todd M. Bauer, Jill S. Clancy, Holger Thurm, Jean‐François Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai‐Hong Ignatius Ou	248
10	The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants 2019 ·Advances in Therapy ·Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P. James, Gerson Peltz, Kimberly Lee, (unknown), (unknown), Yazdi K. Pithavala	24
11	OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 2018 ·Journal of Thoracic Oncology ·S-H.I. Ou, Alice T. Shaw, G. Riely, Rita Chiari, Jessica R. Bauman, Jill S. Clancy, (unknown), Gerson Peltz, Antonello Abbattista, Benjamin Solomon	16
12	Lorlatinib in patients (Pts) with previously treated ALK⁺ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. 2018 ·Journal of Clinical Oncology ·Benjamin Besse, Benjamin Solomon, Enriqueta Felip, Todd M. Bauer, Sai‐Hong Ignatius Ou, Ross A. Soo, D. Ross Camidge, Rita Chiari, Shirish M. Gadgeel, Gregory J. Riely, Eng Huat Tan, Hidetoshi Hayashi, Julien Mazières, Holger Thurm, Jean‐François Martini, Antonello Abbattista, Gerson Peltz, Jill S. Clancy, Alice T. Shaw	12
13	Perinatal factors and breast cancer risk among Hispanics 2013 ·SHILAP Revista de lepidopterología ·Maureen Sanderson, Adriana Pérez, (unknown), (unknown), Gerson Peltz, Vincent Agboto, (unknown), (unknown)	3
14	Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced Non–Small-Cell Lung Cancer 2013 ·Clinical Lung Cancer ·Eduardo J. Pennella, Coleman K. Obasaju, Gerhardt Pohl, Gerson Peltz, Allicia C. Girvan, Katherine B. Winfree, (unknown), Martin Marciniak, Mark S. Walker, Edward J. Stepanski, Lee S. Schwartzberg, Alex A. Adjei	5
15	A review and characterization of the various perceptions of quality cancer care 2010 ·Cancer ·Ann Colosia, Gerson Peltz, Gerhardt Pohl, Esther Liu, Catherine Copley‐Merriman, Shahnaz Khan, James A. Kaye	13
16	Diabetes, physical activity and breast cancer among Hispanic women 2010 ·Cancer Epidemiology ·Maureen Sanderson, Gerson Peltz, Adriana Pérez, Matthew Johnson, Sally W. Vernon, María E. Fernández, Mary Kay Fadden	23
17	The role of fat mass index in determining obesity 2010 ·American Journal of Human Biology ·Gerson Peltz, (unknown), Maureen Sanderson, Mary Kay Fadden	141
18	Serum Leptin Concentration, Adiposity, and Body Fat Distribution in Mexican-Americans 2007 ·Archives of Medical Research ·Gerson Peltz, Maureen Sanderson, Adriana Pérez, Ken Sexton, (unknown), Mary Kay Fadden	11
19	A Multilevel Analysis of Socioeconomic Status and Prostate Cancer Risk 2006 ·Annals of Epidemiology ·Maureen Sanderson, Ann L. Coker, Adriana Pérez, Xianglin L. Du, Gerson Peltz, Mary Kay Fadden	52
20	Nutrition support in cancer patients: a brief review and suggestion for standard indications criteria 2002 ·Nutrition Journal ·Gerson Peltz	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact